Radius Health Inc. is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine and other therapeutics. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.
Company profile
Website
CEO
G. Kelly Martin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MPM ACQUISITION CORP
SEC CIK
Corporate docs
Subsidiaries
Radius Global Support, Inc. • Radius Health Securities Corporation • Radius International Limited • Radius Health (Ireland) Limited • Radius Pharmaceuticals (Bermuda) Ltd. • Radius Pharmaceuticals, Inc. ...
Latest filings (excl ownership)
15-12G
Securities registration termination
25 Aug 22
8-K
Entry into a Material Definitive Agreement
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Aug 22
Transcripts
Earnings call transcript
2022 Q1
6 May 22
Earnings call transcript
2021 Q4
24 Feb 22
Earnings call transcript
2021 Q3
8 Nov 21
Earnings call transcript
2021 Q2
8 Aug 21
Earnings call transcript
2021 Q1
7 May 21
Earnings call transcript
2020 Q4
25 Feb 21
Earnings call transcript
2020 Q3
7 Nov 20
Earnings call transcript
2020 Q3
5 Nov 20
Earnings call transcript
2020 Q2
10 Aug 20
Earnings call transcript
2020 Q1
9 May 20
Latest ownership filings
SC 13D/A
BB BIOTECH AG
30 Aug 22
4
BIOTECH AG BB
30 Aug 22
SC 13D/A
Velan Capital Investment Management LP
26 Aug 22
SC 13G
ICS OPPORTUNITIES II LLC
17 Aug 22
4
Susan Vissers Lisa
15 Aug 22
4
MACHELLE SANDERS
15 Aug 22
4
Owen Hughes
15 Aug 22
4
Chhaya Shah
15 Aug 22
4
CATHY FRIEDMAN
15 Aug 22
4
Willard H Dere
15 Aug 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 73.06 mm | 73.06 mm | 73.06 mm | 73.06 mm | 73.06 mm | 73.06 mm |
Cash burn (monthly) | (no burn) | 2.22 mm | 2.62 mm | 4.23 mm | (no burn) | 2.29 mm |
Cash used (since last report) | n/a | 48.67 mm | 57.29 mm | 92.53 mm | n/a | 50.17 mm |
Cash remaining | n/a | 24.39 mm | 15.77 mm | -19.47 mm | n/a | 22.88 mm |
Runway (months of cash) | n/a | 11.0 | 6.0 | -4.6 | n/a | 10.0 |
Institutional ownership, Q2 2023
3.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 29.02 mm |
Total shares | 1.76 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Integrated Core Strategies | 1.76 mm | $29.02 mm |